Vedolizumab and Anti-Vedolizumab Antibody, DoseASSURE™ VDZ
Also known as: Anti-integrin drug, Biological monitoring, DoseASSURE, Entyvio, Immunogenicity testing
Use
Provides serum concentrations of vedolizumab and anti-vedolizumab antibodies in order to optimize treatment and facilitate clinical decision-making.
Special Instructions
Not provided.
Limitations
The drug half-life should be considered when interpreting concentrations in non-trough collections. High serum biotin concentrations can interfere with this assay, necessitating a stoppage of biotin intake 72 hours before sample collection. The presence of vedolizumab does not affect the anti-vedolizumab antibody measurement as all positive results are verified by a confirmatory test.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 90794-9 - Vedol + Vedol Ab Pnl SerPl-mCnc
- 86898-4 - Vedolizumab SerPl IA-mCnc
- 86899-2 - Vedolizumab Ab SerPl IA-mCnc
Result Turnaround Time
8-15 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3 mL
Minimum Volume
1 mL
Container
Serum-gel tube, red-top tube, green top (heparin) tube, or lavender top (EDTA) tube
Collection Instructions
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum/plasma in a plastic transport tube.
Patient Preparation
Patients should stop biotin consumption at least 72 hours prior to sample collection.
Storage Instructions
Refrigerate or freeze
Causes for Rejection
Gross hemolysis; gross lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
Other tests from different labs that may be relevant